Hostname: page-component-7c8c6479df-7qhmt Total loading time: 0 Render date: 2024-03-27T02:17:13.569Z Has data issue: false hasContentIssue false

P.002 Exosomal miR-204-5 and miR-632 in CSF are candidate biomarkers for frontotemporal dementia: a GENFI study

Published online by Cambridge University Press:  27 June 2018

R Schneider
Affiliation:
(Toronto)
P McKeever
Affiliation:
(Toronto)
T Kim
Affiliation:
(Toronto)
C Graff
Affiliation:
(Toronto)
J van Swieten
Affiliation:
(Rotterdam)
A Karydas
Affiliation:
(San Francisco)
A Boxer
Affiliation:
(San Francisco)
H Rosen
Affiliation:
(San Francisco)
B Miller
Affiliation:
(San Francisco)
R Laforce Jr
Affiliation:
(Quebec City)
D Galimberti
Affiliation:
(Milan)
M Masellis
Affiliation:
(Toronto)
B Borroni
Affiliation:
(Brescia)
Z Zhang
Affiliation:
(Toronto)
L Zinman
Affiliation:
(Toronto)
JD Rohrer
Affiliation:
(London)
MC Tartaglia
Affiliation:
(Toronto)
J Robertson
Affiliation:
(Toronto)
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Background: To determine whether exosomal microRNAs (miRNAs) in CSF of patients with FTD can serve as diagnostic biomarkers, we assessed miRNA expression in the Genetic FTD Initiative (GENFI) cohort and in sporadic FTD. Methods: GENFI participants were either carriers of a pathogenic mutation or at risk of carrying a mutation because a first-degree relative was a symptomatic mutation carrier. Exosomes were isolated from CSF of 23 -pre-symptomatic and 15 symptomatic mutation carriers, and 11 healthy non-mutation carriers. Expression of miRNAs was measured using qPCR arrays. MiRNAs differentially expressed in symptomatic compared to pre-symptomatic mutation carriers were evaluated in 17 patients with sporadic FTD, 13 patients with sporadic Alzheimer’s disease (AD), and 10 healthy controls (HCs). Results: In the GENFI cohort, miR-204-5p and miR-632 were significantly decreased in symptomatic compared to pre-symptomatic mutation carriers. Decrease of miR-204-5p and miR-632 revealed receiver operator characteristics with an area of 0.89 [90% CI: 0.79-0.98] and 0.81 [90% CI: 0.68-0.93], and when combined an area of 0.93 [90% CI: 0.87-0.99]. In sporadic FTD, only miR-632 was significantly decreased compared to sporadic AD and HCs. Decrease of miR-632 revealed an area of 0.89 [90% CI: 0.80-0.98]. Conclusions: Exosomal miR-204-5p and miR-632 have potential as diagnostic biomarkers for genetic FTD and miR-632 also for sporadic FTD.

Type
POSTER PRESENTATIONS
Copyright
© The Canadian Journal of Neurological Sciences Inc. 2018